Latest From Abaxis Inc.
The conventional wisdom in the medtech industry is to pursue the “razor-razor blade” business model, as each placement of capital equipment generates a lucrative annuity of recurring revenues from disposables. The corollary to this conventional wisdom is that so-called “big iron” is to be avoided as, in sharp contrast, it suffers from greater early cash requirements and longer sales cycles that create difficulties forecasting quarterly revenues, and provides no annuities. But that view is no longer the only one that counts, Health Advances CEO Mark Speers argues.
The volume of applications for diagnostic test waivers under the Clinical Laboratory Improvement Amendments increased fivefold in FY 2014, but the total numbers are small, and the change may simply reflect routine year-to-year variation.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Questions on how to decontaminate laboratory analyzers are coming into the Centers for Disease Control and Prevention as U.S. laboratories prepare to accept suspected Ebola specimens, an official says.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- Abaxis Inc.
- Senior Management
Clinton H Severson, Chmn., Pres. & CEO
Alberto R Santa Ines, VP, Fin. & CFO
Kenneth P Aron, PhD, CTO
Ross Taylor, VP, Bus. Dev. & Investor Relations
- Contact Info
Phone: (510) 675-6500
3240 Whipple Rd.
Union City, CA 94587
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.